top of page


Advancing industry-leading Dualase genome editors as transformative medicines
®

Dualase uniquely overcomes the limitations and challenges of in vivo genome editing through its two-site mechanism, which enables seamless removal, repair and insertion of small or large sequences
®
Dualase
®
Pipeline


Pipeline of in vivo therapeutics where small Dualase genome editors have a differentiated mechanism of action coupled with single AAV or lipid nanoparticle / polymer encapsulated all-RNA delivery with initial focus on precise removal of expanded DNA repeats
®
Programs in CNS, lung and liver indications where Dualase editors accurately correct the underlying genetic driver of disease with the potential for durable benefits for patients with limited existing therapeutic options
®
In the News
June 11, 2025
Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors
​​​
May 6, 2025​​
​
​
Jul 24, 2023
​
​
Dec 16, 2021
​
​
Dec 7, 2021
​
Specific Biologics Inc. Announces Therapeutic Development Award from the Cystic Fibrosis Foundation
​
®
bottom of page